Loading stock data…
KURA
$8.77-0.06 (-0.68%)
Market ClosedLast close May 1
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kura Oncology, Inc. in the Healthcare sector is trading at $8.77. The stock is currently 30% below its 52-week high of $12.49, remaining 1.6% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why KURA maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.77
Potential Upside
5%
Whystock Fair Value$9.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$31.17+255.4%
Range$15.00 – $76.00
Fundamentals
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; D...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$845.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-113.23%
Volume
Today's trading volume
1.19M
Recent News
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?
Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets
Kura Oncology’s fair value estimate has been adjusted from US$32.27 to US$31.08, a small move that still reflects detailed work behind the numbers. Analysts are weighing upbeat signals around Komzifti’s early launch against more cautious takes tied to price target cuts to levels such as US$15, US$30, and US$36, which you can see in the mix of updated models. Read on to see how these shifting targets, and the reasoning behind them, can help you track the evolving story around Kura. Stay...
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and th